Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Arbutus Biopharma Corporation

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security Type	Security  Class Title	Fee Calculation or Carry Forward Rule	Amount Registered (1)	Proposed Maximum Offering Price Per Unit (2)	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee (3)	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial effective date	Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to Be Paid	Equity	Common Shares, without par value	457(o)	-	-	-	-	-	-	-	-	-
Fees to Be Paid	Equity	Preferred Shares, without par value	457(o)	-	-	-	-	-	-	-	-	-
Fees to Be Paid	Debt	Debt securities	457(o)	-	-	-	-	-	-	-	-	-
Fees to Be Paid	Other	Warrants	457(o)	-	-	-	-	-	-	-	-	-
Fees to Be Paid	Other	Units	457(o)	-	-	-	-	-	-	-	-	-
Fees to Be Paid	Unallocated (Universal) Shelf	Unallocated (Universal) Shelf (1)	457(o)	-	-	$99,554,226.82 (4)	0.00015310	$15,241.75	-	-	-	-
Fees Previously Paid	-	-	-	-	-	-	-	-	-	-	-	-
Carry Forward Securities
Carry Forward Securities	Equity	Common Shares, without par value	415(a)(6)	-	-	-	-	-	S-3	333-260782	November 18, 2021	-
Carry Forward Securities	Equity	Preferred Shares, without par value	415(a)(6)	-	-	-	-	-	S-3	333-260782	November 18, 2021	-
Carry Forward Securities	Debt	Debt securities	415(a)(6)	-	-	-	-	-	S-3	333-260782	November 18, 2021	-
Carry Forward Securities	Other	Warrants	415(a)(6)	-	-	-	-	-	S-3	333-260782	November 18, 2021
Carry Forward Securities	Other	Units	415(a)(6)	-	-	-	-	-	S-3	333-260782	November 18, 2021	-
Carry Forward Securities	Unallocated (Universal) Shelf	Unallocated (Universal) Shelf (4)	415(a)(6)	(4)	-	$200,445,773.18 (4)	0.00009270	-	S-3	333-260782	November 18, 2021	$18,581.32
	Total Offering Amounts					$300,000,000.00		$15,241.75
	Total Fees Previously Paid							-
	Total Fee Offsets							-
	Net Fee Due							$15,241.75

(1) Arbutus Biopharma Corporation (the “Registrant”) is registering under this registration statement such indeterminate number of common shares and preferred shares, such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common shares, preferred shares and/or debt securities, and such indeterminate number of units as may be sold by the Registrant from time to time, which together shall have an aggregate initial offering price not to exceed $300,000,000. If the Registrant issues any debt securities at an original issue discount, then the offering price of such debt securities shall be in such greater principal amount at maturity as shall result in an aggregate offering price not to exceed $300,000,000, less the aggregate dollar amount of all securities previously issued hereunder. The Registrant may sell any securities the Registrant is registering under this registration statement separately or as units with one or more of the other securities the Registrant is registering under this registration statement. The Registrant will determine, from time to time, the proposed maximum offering price per unit in connection with its issuance of the securities the Registrant is registering under this registration statement. The securities the Registrant is registering under this registration statement also include such indeterminate number of common shares and preferred shares and amount of debt securities as the Registrant may issue upon conversion of or exchange for preferred shares or debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the antidilution provisions of any of such securities. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares the Registrant is registering under this registration statement include such indeterminate number of common shares and preferred shares as may be issuable with respect to the shares the Registrant is registering as a result of shares splits, shares dividends or similar transactions.

(2) The proposed maximum offering price per security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to Instruction 2.A.iii.b of the Instructions to the Calculation of Filing Fee Tables and Related Disclosure of Form S-3.

(3) Calculated pursuant to Rule 457(o) under the Securities Act based on the proposed maximum aggregate offering price of all securities listed.

(4) Pursuant to Rule 415(a)(6) under the Securities Act, securities with a maximum aggregate price of $200,445,773.18 registered hereunder are unsold securities (the “Unsold Securities”) previously covered by the Registrant’s registration statement on Form S-3 (File No. 333-260782) which was initially filed with the Securities and Exchange Commission on November 4, 2021 and became effective on November 18, 2021 (the “Prior Registration Statement”), and are included in this registration statement. The Registrant paid a filing fee of $18,581.32 (calculated at the filing fee rate in effect at the time of the filing of the Prior Registration Statement) relating to the Unsold Securities under the Prior Registration Statement, and no additional filing fee is due with respect to the Unsold Securities in connection with the filing of this registration statement. During the grace period afforded by Rule 415(a)(5) under the Securities Act, the Registrant may continue to offer and sell under the Prior Registration Statement the Unsold Securities being registered hereunder. To the extent that, after the filing date hereof and prior to the effectiveness of this registration statement, the Registrant sells any Unsold Securities under the Prior Registration Statement, the Registrant will identify in a pre-effective amendment to this registration statement the updated number of Unsold Securities from the Prior Registration Statement to be included in this registration statement pursuant to Rule 415(a)(6) and the updated amount of new securities to be registered on this registration statement. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.